Initiator Pharma (Q3 Review): Bolstered finances with readout in sight - Redeye
Bildkälla: Stockfoto

Initiator Pharma (Q3 Review): Bolstered finances with readout in sight - Redeye

Redeye provides a research update following the Q3 report recently published by Initiator Pharma. Operating costs came in below our estimates as the phase IIa study in vulvodynia approached completion, and cash utilization benefited from working capital effects. After the period, the company announced that the last patient has been dosed in the study, with topline data expected in February 2027, and strengthened its financial position through a directed issue of approximately DKK8.2m. Having adjusted for the dilution and cash injection from the directed issue, we lowered our fair value to SEK5 (6) per share.

Redeye provides a research update following the Q3 report recently published by Initiator Pharma. Operating costs came in below our estimates as the phase IIa study in vulvodynia approached completion, and cash utilization benefited from working capital effects. After the period, the company announced that the last patient has been dosed in the study, with topline data expected in February 2027, and strengthened its financial position through a directed issue of approximately DKK8.2m. Having adjusted for the dilution and cash injection from the directed issue, we lowered our fair value to SEK5 (6) per share.
Börsvärldens nyhetsbrev